OHE at Virtual ISPOR May 2021

 The Virtual ISPOR US 2021 – themed ‘HEOR: Evolving for Tomorrow’s Challenge’ – commences this week. A number of researchers from OHE will be in attendance to present their research. Be sure to catch their sessions listed below. For full details on the event please check the ISPOR online program.

ISSUE PANELS

Thursday, May 20, 2021

10:00am - 11:00am EDT (3:00pm - 4:00pm BST),

Christopher Sampson, PhD, will be on the panel titled Drop Dead – Is it Time to Remove ‘Dead’ from Health State Valuation? He will argue in favour of the 'drop dead' motion, describing the origins of the use of 'dead', arguing that it lacks foundations in either utility theory or applied cost-effectiveness analysis. He will suggest some practical alternatives.

The panel will also include Bram Roudijk, PhD (EuroQoL Research Group, Rotterdam, ZH, Netherlands), and will be moderated by Jacoline Bouvy, PhD (National Institute for Health and Care Excellence, London, United Kingdom).

11:30am - 12:30pm EDT (4:30pm - 5:30pm BST)

Adrian Towse, MA, MPhil, will be moderating the session titled When is a QALY not a QALY? Challenges in Introducing and Applying Modifiers in HTA Decision-Making. Martina Garau, MSc, will put the ICER and NICE approaches in the context of approaches proposed in the literature for capturing multiple criteria in decision-making; exploring the extent to which these are used elsewhere; exploring whether HTA can benefit from improving quality and consistency in decision making.

The other panellists for this discussion will be Steven Pearson, MD, MSc (Institute for Clinical and Economic Review, Boston, MA, USA) and Pilar Pinilla, MSc (National Institute for Health and Care Excellence, London, United Kingdom).

POSTER PRESENTATIONS

Wednesday, May 19, 2021

11:30am - 1:45pm EDT (4:30pm - 6:45pm BST)

Simon Brassel will be part of the virtual live author discussion to present his research, titled Recognising the Broader Value of Vaccines in HTA – Ready for the Prime Time?

The COVID-19 pandemic shows that the impact of effective vaccines extends well beyond vaccinated individuals and healthcare systems. While the importance of these externalities is broadly recognised by health economists, they are not typically considered in HTA. This may underestimate vaccines’ broader value and lead to suboptimal allocation decisions. Hence, the objectives of this study were to: 1) prioritise elements of broader value that are most important a/o feasible to be incorporated in vaccine assessments; (2) identify critical challenges and opportunities for including these broader value elements in HTA; 3) explore ways to overcome these including data, methods and policy advancements needed.

Related Research

Brassel, S., Neri, M., and Steuten, L., 2021. Realising the Value of Vaccines in the UK: Ready for Prime Time? OHE Consulting Report, London: Office of Health Economics. Available at: https://www.ohe.org/publications/realising-broader-value-vaccines-uk-ready-prime-time

Sampson, C., Parkin, D. and Devlin, N., 2020. Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation? OHE Research Paper, London: Office of Health Economics. Available at: https://www.ohe.org/publications/drop-dead-anchoring-%E2%80%98dead%E2%80%99-theoretical-requirement-health-state-valuation

Zhang, K., Garau, M. (2020). International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making. OHE Consulting Report, London: Office of Health Economics. Available at: International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making | OHE

 

Posted in General, Research | Tagged Presentations